Summary of Key Points Core Viewpoint - The company has provided a joint liability guarantee for its subsidiary, Sichuan Bencao Tang Pharmaceutical Co., Ltd., which has a debt-to-asset ratio exceeding 70%, indicating potential risks associated with the guarantee [2][11]. Group 1: Guarantee Overview - The company approved a guarantee for Sichuan Bencao Tang to apply for a comprehensive credit limit of up to 1.368 billion RMB for financing needs [2][4]. - A maximum guarantee contract was signed with China Minsheng Bank Chengdu Branch, with the principal amount guaranteed being up to 100 million RMB [3][10]. Group 2: Subsidiary Information - Sichuan Bencao Tang Pharmaceutical Co., Ltd. is a wholly-owned subsidiary with a registered capital of 125 million RMB, established on August 16, 2004 [5][6]. - The company holds a 56% stake in Sichuan Bencao Tang, which is engaged in various pharmaceutical and healthcare-related activities [6][7]. Group 3: Guarantee Agreement Details - The guarantee covers the principal debt, interest, penalties, and all costs associated with enforcing the debt and guarantee rights [8]. - The guarantee period is three years from the maturity date of each debt under the main contract [9]. Group 4: Necessity and Reasonableness of Guarantee - The guarantee is deemed necessary for the subsidiary's daily operations, with other shareholders providing counter-guarantees [11]. - The subsidiary is considered to have a normal debt repayment capacity, and the risks associated with the guarantee are manageable [11]. Group 5: Cumulative External Guarantee Amount - After this guarantee, the total external guarantee amount by the company and its subsidiaries is 1.28227 billion RMB, with a total balance of 903.1863 million RMB, accounting for 11.80% of the company's audited net assets for 2024 [12].

股票代码：002727 股票简称：一心堂 公告编号：2025-090 号 一心堂药业集团股份有限公司 关于控股子公司四川本草堂药业有限公司 向银行申请授信额度提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 一心为民 全心服务 一心堂药业集团股份有限公司(以下简称"公司")本次为控股子公司四川本草堂药业有限 公司（以下简称"四川本草堂"或"债务人")提供连带责任保证方式的担保，被担保企业四川 本草堂最近一期经审计（2024年12月31日）的资产负债率超过70%，敬请投资者充分关注担保风 险。 一、担保情况概述 公司于 2024 年 12 月 13 日召开 2024 年度第三次临时股东大会，审议通过《关于同意子公 司向相关银行申请综合授信额度并为其提供担保的议案》，同意公司担保下属子公司向相关银 行申请综合授信共计 13.68 亿元，用于子公司融资业务，具体额度在不超过 13.68 亿元的金额 上限内以银行授信为准，以上综合授信的金额在一年内以银行授信为准。《关于同意子公司向 相关银行申请综合授信额度并为其提供担保的公告》详见公司指 ...

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-088 号 一心堂药业集团股份有限公司 关于使用部分暂时闲置 2018 年公开发行可转换公司债券 募集资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司(以下简称"公司")于2025年5月21日召开2024年年度股东会， 审议通过《关于使用部分暂时闲置2018年公开发行可转换公司债券募集资金进行现金管理的议 案》，同意公司使用额度不超过人民币3.25亿元的2018年公开发行可转换公司债券的暂时闲置 募集资金进行现金管理（包括但不限于购买一年期以内的固定收益型或保本浮动收益型理财产 品、大额存单、定期存款、通知存款、协定存款等），以上额度为在投资期限内任一时点的现 金管理金额(含前述投资的收益进行再投资的相关金额)不超过3.25亿元人民币。在上述额度内， 资金可以滚动使用，在额度范围内授权董事长具体办理实施相关事项。独立董事、保荐机构对 上述议案发表了审查意见。 一、使用部分暂时闲置 2018 年公开发行可转换公司债券募集资金进行 ...

一心为民 全心服务 一、使用部分暂时闲置自有资金进行现金管理情况 一心堂药业集团股份有限公司 关于使用部分暂时闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司(以下简称"公司")于2025年5月21日召开2024年年度股东会， 审议通过《关于使用部分暂时闲置自有资金进行现金管理的议案》，同意公司及全资子公司使 用额度不超过人民币25亿元的闲置自有资金进行现金管理（包括但不限于购买一年期以内的固 定收益型或保本浮动收益型理财产品、大额存单、定期存款、通知存款、协定存款等），相关 额度在投资期限内任一时点的现金管理金额(含前述投资的收益进行再投资的相关金额)不超过 25亿元人民币。在上述额度内，资金可以滚动使用，在额度范围内授权董事长具体办理实施相 关事项。 股票代码：002727 股票简称：一心堂 公告编号：2025-089 号 （一）本次进行现金管理基本情况 近日，公司分别与广发银行股份有限公司昆明万宏支行及上海浦东发展银行股份有限公司 昆明分行签订了《结构性存款产品合同》，本次进行现金管理基本情况 ...

Core Viewpoint - The offline pharmacy industry is undergoing a significant transformation, shifting from rapid expansion to a focus on optimization and quality improvement, with many companies facing declining performance and store closures as a result of changing market dynamics and regulatory pressures [1][7]. Industry Performance - In the first half of 2025, several listed offline pharmacy companies reported weak performance, with major players like Yifeng Pharmacy, Lao Baixing, and Yixin Tang experiencing revenue declines [2]. - The retail pharmacy sector is seeing a slowdown in revenue growth, with some companies reporting negative growth for the first half of 2025, marking the end of a 20-year period of high growth [2][4]. Store Closures and Strategic Adjustments - Major pharmacy chains are closing stores to optimize their operations, with Yifeng Pharmacy closing 1,078 stores and Daclin closing 733 stores in 2024 [5]. - Guoda Pharmacy, once a member of the "10,000 store club," has closed over 1,270 stores as part of its strategic shift towards high-quality development, reducing its total store count from 10,702 to 9,569 by the end of 2024 [2][6]. Market Trends and Future Outlook - The overall retail pharmacy market is experiencing a contraction, with a significant decrease in the number of stores, dropping below 700,000 nationwide by the first quarter of 2025 [6]. - The industry is expected to undergo consolidation, with a shift from quantity expansion to quality improvement, driven by regulatory changes and market pressures [7][8]. - The rise of online pharmacy services is impacting traditional brick-and-mortar stores, but the latter are adapting by enhancing their service offerings and focusing on prescription drugs and health products [8].

Core Viewpoint - YXTT announced the decision to use its own funds to pay for part of the fundraising project costs, which will later be replaced with equivalent amounts from the raised funds, aiming to enhance operational management efficiency without affecting the normal progress of the fundraising projects [1] Summary by Relevant Sections - **Board Meeting Announcement** - YXTT will hold its sixth board meeting on September 29, 2025, to review the proposal regarding the use of self-owned funds for fundraising project payments [1] - **Operational Efficiency** - The company aims to improve operational management efficiency by initially using its own funds for certain project costs, with plans to replace these amounts with raised funds later [1] - **Fund Replacement Mechanism** - The equivalent amounts used from the company's own funds will be treated as funds utilized for the fundraising projects, ensuring that the fundraising project implementation remains unaffected [1]

Core Points - Yixin Tang Pharmaceutical Group Co., Ltd. held its 17th meeting of the 6th Board of Directors on September 29, 2025, with all 9 directors present [1] - The meeting approved a proposal to use self-owned funds to pay part of the investment project costs and replace them with an equivalent amount of raised funds [1] - The proposal received unanimous approval with 9 votes in favor, 0 against, and 0 abstentions [1] Summary by Sections - **Meeting Details** - The meeting was conducted both in-person and via communication methods at the company's conference room [1] - The meeting was presided over by Mr. Huan Hongxian [1] - **Proposal Approval** - The proposal to use self-owned funds for investment project costs was reviewed and approved [1] - The proposal was verified by the sponsor, Dongxing Securities Co., Ltd., and the independent directors also expressed their agreement [1] - **Documentation** - The announcement includes documents for reference, such as the resolution of the 17th meeting of the 6th Board of Directors and other required documents by the Shenzhen Stock Exchange [1]

Group 1 - YXTT announced the convening of its 17th board meeting on September 29, 2025, to discuss the use of self-owned funds for certain fundraising projects and the replacement of raised funds with equivalent amounts [1] - For the first half of 2025, YXTT's revenue composition was as follows: retail accounted for 73.14%, wholesale for 23.68%, and other businesses for 3.17% [1] - As of the report, YXTT's market capitalization stood at 8.2 billion [1] Group 2 - The competition between Farmer and Yibao has intensified, with Farmer's green bottle launch leading to a significant market share decline for Yibao, dropping nearly 5 percentage points [1]

东兴证券股份有限公司 关于一心堂药业集团股份有限公司 使用自有资金支付募投项目部分款项并以募集资金等额置 换的核查意见 东兴证券股份有限公司（以下简称"东兴证券"、"保荐人"）作为一心堂药 业集团股份有限公司（以下简称"一心堂"、"公司"）2018 年度公开发行可转换 公司债券的保荐人，根据《证券发行上市保荐业务管理办法》《上市公司募集资 金监管规则》（证监会公告[2025]10 号）《深圳证券交易所股票上市规则》《深圳 证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等有关规 定，对一心堂使用自有资金支付募投项目部分款项并以募集资金等额置换事项进 行了核查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会于 2018 年 10 月 23 日出具的《关于核准云南鸿 翔一心堂药业（集团）股份有限公司公开发行可转换公司债券的批复》（证监许 可[2018]2160 号）核准，一心堂药业集团股份有限公司于 2019 年 4 月 19 日向社 会公众公开发行面值不超过 60,263.92 万元的可转换公司债券，每张面值 100 元， 按面值平价发行，发行总额 60,263.92 万元。上 ...

一心堂药业集团股份有限公司 第六届董事会 2025 年第五次独立董事专门会议审核意见 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司独立董 事管理办法》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规 范运作》等法律、行政法规、中国证券监督管理委员会行政规章和规范性文件、深 圳证券交易所相关规则及规定以及《一心堂药业集团股份有限公司章程》等有关规 定，一心堂药业集团股份有限公司（以下简称"公司"）独立董事于 2025 年 9 月 22 日召开了第六届董事会 2025 年第五次独立董事专门会议。独立董事本着实事求 是、认真负责的态度，公平、公正、诚实信用的原则，基于独立判断的立场，对公 司第六届董事会第十六次会议相关事项进行了认真审核，并发表审核意见如下： 一、关于使用自有资金支付募投项目部分款项并以募集资金等额置换的议案 公司使用自有资金支付募投项目所需资金并以募集资金等额置换的事项，是基 于公司募集资金使用计划实施的具体需要，有助于推进募投项目的建设发展。该募 集资金的使用方式、用途及决策程序符合《上市公司募集资金监管规则》《深圳证 券交易所股票上市规则》《深圳证券交易所上市 ...